4.7 Article

Amide-based Prodrugs of spermidine-bridged dinuclear platinum. Synthesis, DNA binding, and biological activity

Journal

JOURNAL OF MEDICINAL CHEMISTRY
Volume 51, Issue 7, Pages 2254-2260

Publisher

AMER CHEMICAL SOC
DOI: 10.1021/jm070813z

Keywords

-

Funding

  1. Howard Hughes Medical Institute Funding Source: Medline
  2. NCI NIH HHS [R01 CA078754-10A1, R01 CA 78754, R01 CA078754] Funding Source: Medline

Ask authors/readers for more resources

The chemistry and biology of acetyl-protected spermidine-bridged dinuclear platinum complexes [(trans-PtCl(NH3)(2)](2)-mu-NH2(CH2)(3)N(COR)(CH2)(4)NH2]X-2 (R = H, X = C1 (1,1/t,t-spermidine, BBR3571); R = CH3, X = Cl (2); R = CH2 Cl, X = ClO4 (3); R = CF3, X = Cl (4)) are compared with their carbamate analogues. The compounds are potential prodrugs for the parent compound 1, a highly potent antitumor agent. At pH 6-8 hydrolysis of the blocking group with the release of the parent protonated species follows the order 4 > 3 >> 2. For 4, rate constants for the deprotection increase in this pH range. The DNA binding profile of 4 is similar to the Boc derivative, confirming the central influence of charge on DNA binding properties. The differences in cytotoxicity for the protected compounds in ovarian carcinoma cell lines sensitive and resistant to cisplatin cannot completely be explained by spontaneous release of 1,1/t,t-spermidine at physiological pH. Inherent cytotoxicity and cell line specificity may contribute to the observed behavior. The properties of the compounds present them also as possible second-generation analogues of the clinically relevant trinuclear complex [{trans-PtCl(NH3)(2)}(2)-mu-trans-Pt(NH3)(2)(NH2(CH2)(6)NH2)(2)](NO3)(4), (8, BBR3464).

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available